Development asset linked to Genmab in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
pharma · Lymphoma of B-cell origin · Malignant Solid Tumors
Genmab
Genmab A/S
Genmab drug portfolio — 56 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Carl Jacobsens Vej 30, 2500 Valby, DK HQ
2,847 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Carl Jacobsens Vej 30, 2500 Valby, DK
- Employees
- 2,847
- Programs
- 29
- Drugs
- 56
- Patents
- 0
Genmab pipeline
Portfolio lens on 56 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Genmab drug portfolio — 56 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
anakinra
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.
- Target
- Interleukin-1 receptor type 1
- Mechanism
- Interleukin-1 receptor antagonist
-
Development asset linked to Genmab in public FDA and regional records.
-
Development asset linked to Genmab in public FDA and regional records.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Genmab in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Genmab's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
epcoritamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Genmab's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
filgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
fingolimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.
- Mechanism
- Sphingosine 1-phosphate receptor binding agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Genmab in public FDA and regional records.
-
Development asset linked to Genmab in public FDA and regional records.
-
Development asset linked to Genmab in public FDA and regional records.
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to Genmab in public FDA and regional records.
-
Development asset linked to Genmab in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Genmab in public FDA and regional records. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Genmab in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
pegfilgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pemetrexed
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
pirtobrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
Development asset linked to Genmab in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
siltuximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6.
- Target
- Interleukin-6
- Mechanism
- Interleukin-6 inhibitor
-
Development asset linked to Genmab in public FDA and regional records.
-
Development asset linked to Genmab in public FDA and regional records.
-
Development asset linked to Genmab in public FDA and regional records.
-
tisotumab vedotin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Genmab's portfolio. Molecular target: Tissue factor.
- Target
- Tissue factor
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Tissue factor.
- Target
- Tissue factor
- Mechanism
- Coagulation factor III binding agent
-
tocilizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor
-
Development asset linked to Genmab in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor